Javascript must be enabled to continue!
When drugs and surgery don’t work
View through CrossRef
SummaryEpilepsy is a chronic disorder characterized by recurrent and unprovoked seizures (Dreifuss, 1987; Hauser & Hesdorffer, 1990). It is one of the most common neurologic disorders in the adult. The lifetime risk of developing epilepsy is 3.2% (Mattson, 1992). Approximately 90% of the incident cases in adults have symptomatic partial or localization‐related epilepsy (Camfield & Camfield, 1996; Hauser & Hesdorffer, 1990; Hauser, 1992). The medial temporal lobe is the most epileptogenic region of the brain (Luby et al., 1995; Jeong et al., 1999; Wiebe et al., 2001). Pathologic lesions underlying the epileptogenic zone include mesial temporal sclerosis (MTS), tumor, vascular anomaly, malformations of cortical development (MCDs), and head trauma (Cascino et al., 1993; Radhakrishnan et al., 1998). The initial response to medication is of prognostic importance (Hauser, 1992). Patients with a remote symptomatic neurologic disease, foreign‐tissue lesion, developmental delay, or abnormal neurologic examination are less likely to be rendered seizure‐free. The goals of treatment are to render the individual seizure‐free without producing antiepileptic drug (AED) toxicity, allowing the individual to become a participating and productive member of society (Engel & Ojemann, 1993). Despite the introduction of “newer” AEDs, nearly one‐half of patients with partial epilepsy will not attain a seizure remission with pharmacotherapy (Kwan & Brodie, 2003). This discussion focuses on management of the adult patient with intractable partial seizure disorders that are medically refractory and may not be surgically remediable. It is estimated that 400,000 of the 2 million individuals with partial epilepsy in the United States have a medically refractory partial seizure disorder (Hauser & Hesdorffer, 1990; Hauser, 1992). An estimated 1,500 patients in the United States undergo epilepsy surgery each year. A UK study indicated that 30,000 patients develop epilepsy each year and approximately 6,000 have medically refractory seizures (Lhatoo et al., 2003). However, there are only about 400 epilepsy surgeries performed annually in the UK. Therefore, the number of patients with intractable partial epilepsy that is both medically refractory and possibly not a surgically remediable epileptic syndrome is significant.
Title: When drugs and surgery don’t work
Description:
SummaryEpilepsy is a chronic disorder characterized by recurrent and unprovoked seizures (Dreifuss, 1987; Hauser & Hesdorffer, 1990).
It is one of the most common neurologic disorders in the adult.
The lifetime risk of developing epilepsy is 3.
2% (Mattson, 1992).
Approximately 90% of the incident cases in adults have symptomatic partial or localization‐related epilepsy (Camfield & Camfield, 1996; Hauser & Hesdorffer, 1990; Hauser, 1992).
The medial temporal lobe is the most epileptogenic region of the brain (Luby et al.
, 1995; Jeong et al.
, 1999; Wiebe et al.
, 2001).
Pathologic lesions underlying the epileptogenic zone include mesial temporal sclerosis (MTS), tumor, vascular anomaly, malformations of cortical development (MCDs), and head trauma (Cascino et al.
, 1993; Radhakrishnan et al.
, 1998).
The initial response to medication is of prognostic importance (Hauser, 1992).
Patients with a remote symptomatic neurologic disease, foreign‐tissue lesion, developmental delay, or abnormal neurologic examination are less likely to be rendered seizure‐free.
The goals of treatment are to render the individual seizure‐free without producing antiepileptic drug (AED) toxicity, allowing the individual to become a participating and productive member of society (Engel & Ojemann, 1993).
Despite the introduction of “newer” AEDs, nearly one‐half of patients with partial epilepsy will not attain a seizure remission with pharmacotherapy (Kwan & Brodie, 2003).
This discussion focuses on management of the adult patient with intractable partial seizure disorders that are medically refractory and may not be surgically remediable.
It is estimated that 400,000 of the 2 million individuals with partial epilepsy in the United States have a medically refractory partial seizure disorder (Hauser & Hesdorffer, 1990; Hauser, 1992).
An estimated 1,500 patients in the United States undergo epilepsy surgery each year.
A UK study indicated that 30,000 patients develop epilepsy each year and approximately 6,000 have medically refractory seizures (Lhatoo et al.
, 2003).
However, there are only about 400 epilepsy surgeries performed annually in the UK.
Therefore, the number of patients with intractable partial epilepsy that is both medically refractory and possibly not a surgically remediable epileptic syndrome is significant.
Related Results
Global Surgery Research: An Overview and the Role of Medical Students and Surgical Trainees in Advancing Global Surgery Research in LMICs
Global Surgery Research: An Overview and the Role of Medical Students and Surgical Trainees in Advancing Global Surgery Research in LMICs
Global surgery research is a critical area of study aimed at enhancing access to safe and effective surgical care for patients in low- and middle-income countries (LMICs). It is es...
Interview: Kari Tikkinen
Interview: Kari Tikkinen
What initially sparked your interest in medicine, and what led you specifically to the field of urology?
I was not sure about medicine until I was almost 20. In high school I was t...
Health policies and programs facilitating access to high-cost anticancer drugs
Health policies and programs facilitating access to high-cost anticancer drugs
Access to anticancer drugs is limited mainly due to their high cost. To support policymakers in Thailand to develop policies and programs to facilitate better access to high-cost a...
PROMs in Total Hip Arthroplasty: A Comparison between Robotic Mako Assisted Versus Manual Technique
PROMs in Total Hip Arthroplasty: A Comparison between Robotic Mako Assisted Versus Manual Technique
Study Purpose: The purpose of this observational study is to evaluate the degree of satisfaction and improvement in quality of life through PROMs (Patient Related Outcome Measures)...
Abstract P4-07-01: Overall survival with locoregional surgery in de novo metastatic breast cancer
Abstract P4-07-01: Overall survival with locoregional surgery in de novo metastatic breast cancer
Abstract
Background: Breast cancer remains the most frequent type of cancer in women, with de novo metastatic breast cancer (dnMBC) accounting for approximately 6-10...
Chest Wall Hydatid Cysts: A Systematic Review
Chest Wall Hydatid Cysts: A Systematic Review
Abstract
Introduction
Given the rarity of chest wall hydatid disease, information on this condition is primarily drawn from case reports. Hence, this study systematically reviews t...
Using 5 consecutive years of NICE guidance to describe the characteristics and influencing factors on the economic evaluation of orphan oncology drugs
Using 5 consecutive years of NICE guidance to describe the characteristics and influencing factors on the economic evaluation of orphan oncology drugs
ObjectiveOrphan oncology drugs used in this article were defined by the type of disease treated by drugs, as drugs used to treat rare diseases with a prevalence of ≤ 500 per millio...
COST-EFFECTIVENESS OF ORPHAN DRUGS FOR LEUKEMIA TREATMENT: A SYSTEMATIC REVIEW
COST-EFFECTIVENESS OF ORPHAN DRUGS FOR LEUKEMIA TREATMENT: A SYSTEMATIC REVIEW
Introduction: Leukemia is a rare disease related to hematologic cancer stemming from the bone marrow. The Vietnam Ministry of Health (MOH) promulgated the Orphan Drugs List, in whi...

